Results 51 to 60 of about 17,845 (225)

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

British Journal of Clinical Pharmacology, EarlyView.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf, Ymke van der Velde, Paul R. V. Malik, Jelmer R. Prins, Sanne J. Gordijn, Daan J. Touw, Paola Mian   +6 more
wiley   +1 more source

Role of Dolutegravir-based antiretroviral treatment in achieving an undetectable HIV-1 viral load among women attending prevention of mother-to-child transmission clinics in Addis Ababa, Ethiopia

SAGE Open Medicine
Objectives: This study aimed to determine the prevalence of detectable HIV-1 viral load and associated factors among pregnant and lactating women on Dolutegravir-based and non-Dolutegravir-based regimens.
Belete Woldesemayat, Yimam Getaneh, Sisay Adane, Ajanaw Yizengaw, Amelework Yilma, Shambel Araya Haile, Kidist Zealiyas   +6 more
doaj   +1 more source

HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.

PLoS ONE, 2020
ObjectivesAging HIV-infected antiretroviral-treatment (ART)-controlled patients often present cardiovascular and metabolic comorbidities. Thus, it is mandatory that life-long used ART has no cardiometabolic toxicity.
Martine Auclair, Anne-Claire Guénantin, Soraya Fellahi, Marie Garcia, Jacqueline Capeau   +4 more
doaj   +1 more source

Dolutegravir-Associated Resistance Mutations in Brazil

, 2023
Dolutegravir-Associated Resistance Mutations after first-line treatment failure in ...
James R. Hunter, Ricardo Sobhie Diaz, Mauro Schechter   +2 more
core   +1 more source

A multidisciplinary, AI‐supported quality improvement intervention to manage polypharmacy in aging people with HIV

HIV Medicine, EarlyView.
Abstract Objectives Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older ...
Jovana Milic, Antonia Pugliese, Michela Belli, Gian Luca Lonardi, Caterina Ruffilli, Tommaso Albano, Marco Visicaro, Martina Ricciardetto, Pierluigi De Cosmo, Chiara Mussi, Francesca Gandolfi, Cristina Mussini, Costantino Grana, Giovanni Guaraldi   +13 more
wiley   +1 more source

The Global Implementation of Dolutegravir for HIV Treatment

, 2022
BackgroundDolutegravir, an integrase strand transfer inhibitor, is now recommended by international guidelines as part of preferred antiretroviral therapy (ART) regimens for people living with HIV.
Romo, Matthew L.
core  

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

HIV Medicine, EarlyView.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson, Peter Dutey‐Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas‐Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler, François Raffi, Andrea Calcagno, Ab Babiker, Alan Winston   +13 more
wiley   +1 more source

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

The Lancet Global Health, 2018
Summary: Background: Global rollout of dolutegravir-based antiretroviral therapy (ART) has been hampered in part by insufficient safety data in pregnancy.
Rebecca Zash, MD, Denise L Jacobson, PhD, Modiegi Diseko, BA, Gloria Mayondi, BSc, Mompati Mmalane, MD, Max Essex, ProfPhD, Tendani Gaolethe, MD, Chipo Petlo, BA, Shahin Lockman, MD, Lewis B Holmes, MD, Joseph Makhema, MBBS, Roger L Shapiro, MD   +11 more
doaj   +1 more source

Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus

SAGE Open Medical Case Reports, 2022
HIV-infected people have started to live longer since the introduction of antiretroviral therapy, however various co-morbid illnesses have emerged. Three HIV-infected individuals, all at least 43 years old, reported with a new onset of type 2 diabetes ...
Agete Tadewos Hirigo, Selamawit Gutema, Aberash Eifa, Worku Ketema   +3 more
doaj   +1 more source

Efficacy of dolutegravir/lamivudine in adults with HIV‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

HIV Medicine, EarlyView.
Abstract Objectives As two‐drug HIV‐1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti‐HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three‐ or four‐drug regimens (3DRs/4DRs ...
D. Fox, J. Slim, E. T. Overton, A. Doblado‐Maldonado, P. Jeffery, R. A. Grove, S. D. Advani, R. Borsi, C. M. Parry, M. Underwood, B. Jones   +10 more
wiley   +1 more source